Anzeige
Mehr »
Login
Donnerstag, 07.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
605 Leser
Artikel bewerten:
(2)

Dukosi Ltd: Dukosi Expands Technical Advisory Board with Appointment of Stefan Juraschek and Dr Anna Stefanopoulou as Advisors

BMW Group Veteran and University of Michigan Professor Bring Decades of Expertise in Automotive Electronic Systems and Battery Modeling and Control to Chip-on-Cell Technology Pioneer

EDINBURGH, Scotland, Dec. 12, 2023 /PRNewswire/ -- Dukosi Ltd, the technology company revolutionizing the performance, safety and sustainability of battery systems, today announced former BMW executive Stefan Juraschek and Dr Anna Stefanopoulou, William Clay Ford Professor of Technology in the Department of Mechanical Engineering at the University of Michigan, will join Bob Galyen on the Dukosi Technical Advisory Board (TAB). Stefan Juraschek brings decades of experience leading research and development (R&D) in automotive electric/electronic products and processes at the global automotive brand. Dr Stefanopoulou who is a renowned researcher in the field of electrochemical processes brings a wealth of knowledge in battery modeling and control to improve safety in battery systems used in electric mobility and energy storage applications. Dukosi also announced Joel Sylvester, Founder and CTO of Dukosi, will become Chair of the Technical Advisory Board.

Dukosi Ltd Logo

"We are excited to welcome Stefan and Anna to the Dukosi Technical Advisory Board," said Mark Pinto, CEO of Dukosi. "Anna's deep understanding of battery chemistries and modeling will help build our product roadmap of cell monitoring solutions that provide unparalleled safety as the industry moves toward higher energy density batteries. Stefan's extensive experience driving R&D programs at BMW Group broadens the TAB's expertise with automotive know-how gained from his more than 30 years' tenure in the development programs at the German multinational manufacturer of luxury vehicles. Not only are they both well-known and respected by peers in industry and research, both share Dukosi's commitment to enabling an electric future and building a circular and sustainable battery value chain."

Stefan Juraschek is an automotive industry veteran with more than three decades of experience in managing electric and electronic systems design and development for several vehicle programs at BMW Group. Over the course of his career at BMW, he has been responsible for managing the development of BEV and hybrid electric powertrains and the associated components, Electric/Electronic architectures, software development and system integration and test. He has held multiple vice president (VP) roles, including VP R&D Driving Dynamics, VP R&D Powertrain where he was also responsible for cell, battery and BMS development, and most recently VP R&D Electric/Electronic.

Dr Anna G Stefanopoulou is the William Clay Ford Professor of Technology and Professor of Mechanical Engineering at the University of Michigan. Dr Stefanopoulou is a celebrated researcher in the field of battery modeling and control with focus in electrochemical processes and improving safety in battery systems. She received Masters degrees in Electrical Engineering and Computer Science and Naval Architecture and Marine Engineering, and a Ph.D. in Electrical Engineering and Computer Science from the University of Michigan. Dr Stefanopoulou has been recognized as a Fellow of three different societies; the ASME (2008), IEEE (2009), and SAE (2018). She has co-authored a book, has 20 US patents, and more than 250 publications (5 of which have received awards) on estimation and control of internal combustion engines and electrochemical processes such as fuel cells and batteries.

About Dukosi

Dukosi develops revolutionary technologies that dramatically improve the performance, safety, and efficiency of battery systems, and enable a more sustainable battery value chain. The company provides a unique cell monitoring platform based on chip-on-cell technology and C-SynQ® communications protocol for electric vehicles (EV), industrial transportation and stationary battery energy storage markets. Headquartered in Edinburgh, UK, Dukosi has a global footprint with locations in USA, Asia and Europe.

For more information, please visit www.dukosi.com

Logo - https://mma.prnewswire.com/media/2201070/4447048/dukosi_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/dukosi-expands-technical-advisory-board-with-appointment-of-stefan-juraschek-and-dr-anna-stefanopoulou-as-advisors-302012439.html

© 2023 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.